Digestive and Liver Disease
Volume 42, Issue 7 , Pages 496-502 , July 2010

No beneficial effects of amantadine in treatment of chronic hepatitis C patients

  • Hanneke van Soest

      Affiliations

    • Dept. of Gastroenterology and Hepatology, University Medical Center Utrecht, The Netherlands
    • ,
  • Peter J. van der Schaar

      Affiliations

    • Dept. of Gastroenterology and Hepatology, Atrium Medical Center Heerlen, The Netherlands
    • ,
  • Ger H. Koek

      Affiliations

    • Dept. of Gastroenterology and Hepatology, University Hospital Maastricht, The Netherlands
    • ,
  • Richard A. de Vries

      Affiliations

    • Dept. of Gastroenterology and Hepatology, Rijnstate Hospital Arnhem, The Netherlands
    • ,
  • Nancy A. van Ooteghem

      Affiliations

    • Dept. of Gastroenterology and Hepatology, St Lucas Andreas Hospital Amsterdam, The Netherlands
    • ,
  • Bart van Hoek

      Affiliations

    • Dept. of Gastroenterology and Hepatology, Leiden University Medical Center, The Netherlands
    • ,
  • Joost P.H. Drenth

      Affiliations

    • Dept. of Gastroenterology and Hepatology, University Hospital Nijmegen, The Netherlands
    • ,
  • Jan M. Vrolijk

      Affiliations

    • Dept. of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, The Netherlands
    • ,
  • Rob J. Lieverse

      Affiliations

    • Dept. of Gastroenterology and Hepatology, Gelre Ziekenhuizen Apeldoorn, The Netherlands
    • ,
  • Peter Houben

      Affiliations

    • Dept. of Gastroenterology and Hepatology, Ziekenhuis Zeeuws Vlaanderen, The Netherlands
    • ,
  • Annet van der Sluys Veer

      Affiliations

    • Dept. of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis Amsterdam, The Netherlands
    • ,
  • Peter D. Siersema

      Affiliations

    • Dept. of Gastroenterology and Hepatology, University Medical Center Utrecht, The Netherlands
    • ,
  • Marguerite E.I. Schipper

      Affiliations

    • Dept. of Pathology, University Medical Center Utrecht, The Netherlands
    • ,
  • Karel J. van Erpecum

      Affiliations

    • Dept. of Gastroenterology and Hepatology, University Medical Center Utrecht, The Netherlands
    • Corresponding Author InformationCorresponding author at: Dept. of Gastroenterology and Hepatology F 02. 618, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. Tel.: +31 88 7557004; fax: +31 88 7555533.
    • ,
  • Greet J. Boland

      Affiliations

    • Dept. of Gastroenterology and Hepatology, University Medical Center Utrecht, The Netherlands
    • Dept. of Virology, University Medical Center Utrecht, The Netherlands

Received 11 January 2009 ,Accepted 28 October 2009.

References 

  1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562
  2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  4. Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982;307:580–584
  5. Koff WC, Elm JL, Halstead SB. Inhibition of dengue virus replication by amantadine hydrochloride. Antimicrob Agents Chemother. 1980;18:125–129
  6. Reuman PD, Bernstein DI, Keefer MC, et al. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res. 1989;11:27–40
  7. Van Voris LP, Betts RF, Hayden FG, et al. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. J Am Med Assoc. 1981;245:1128–1131
  8. Tabone M, Ercole E, Zaffino C, et al. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol. 1998;30:611–613
  9. Caronia S, Bassendine MF, Barry R, et al. Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study. J Hepatol. 2001;35:512–516
  10. Mangia A, Leandro G, Helbling B, et al. Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol. 2004;40:478–483
  11. Brillanti S, Foli M, Di TM, et al. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Ital J Gastroenterol Hepatol. 1999;31:130–134
  12. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci. 1997;42:1681–1687
  13. Berg T, Kronenberger B, Hinrichsen H, et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology. 2003;37:1359–1367
  14. Helbling B, Stamenic I, Viani F, et al. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology. 2002;35:447–454
  15. Mangia A, Minerva N, Annese M, et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology. 2001;33:989–993
  16. Tabone M, Laudi C, Delmastro B, et al. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol. 2001;35:517–521
  17. Steinmann E, Whitfield T, Kallis S, et al. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology. 2007;46:330–338
  18. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231–264
  19. Mangia A, Ricci GL, Persico M, et al. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs. interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat. 2005;12:292–299
  20. Angelico M, Koehler-Horst B, Piccolo P, et al. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naive patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2008;20:680–687
  21. von Wagner M, Hofman P, Teuber G, et al. Randomized, double-blind, placebo-controlled trial of Peginterferon alfa-2a (40kD) and ribavirin with and without 400mg amantadine-sulphate for 48 weeks in treatment naive HCV genotype 1-infected patients. Hepatology. 2007;46:S1342
  22. Deltenre P, Henrion J, Canva V, et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol. 2004;41:462–473
  23. Teuber G, Pascu M, Berg T, et al. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol. 2003;39:606–613
  24. Zeuzem S. Induction therapy in chronic hepatitis C: deja-vu with pegylated interferons?. J Hepatol. 2004;41:488–490
  25. Dixit NM, Layden-Almer JE, Layden TJ, et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004;432:922–924
  26. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395–403
  27. Silva IS, Ferraz ML, Perez RM, et al. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2004;19:314–318
  28. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449–1457

☆ This investigator-driven study was supported by a grant by Schering-Plough BV, Maarssen, The Netherlands.

PII: S1590-8658(09)00430-7

doi: 10.1016/j.dld.2009.10.006

Digestive and Liver Disease
Volume 42, Issue 7 , Pages 496-502 , July 2010

Article Tools

* Image Usage & Resolution